| |
March 18-20, 2024 | Savannah, GA The Fierce TMF Summit is the must-attend event for clinical document management professionals to learn, network and connect. Gain invaluable insights from unique case studies, panels, and workshops, and access the best networking the industry has to offer. Register now and SAVE $300 until February 23 to take your TMF to the next level. Sign up today!
|
|
Today’s Big NewsFeb 15, 2024 |
| By Annalee Armstrong The idea to build a company around degrader antibody conjugates—not antibody drug conjugates—had been bubbling for a while. But not just anyone could pick up the gauntlet and fly with it. Firefly Bio, assemble. |
|
|
|
By James Waldron It looks like Ampio Pharmaceuticals’ last shot at getting a therapy to market won’t even make it into the clinic. Animal studies have shown that the Colorado biotech’s OA-201 program was unable to reduce pain caused by osteoarthritis. |
By James Waldron Aurinia Pharmaceuticals searched long and hard for a potential buyer, but faced with a lack of serious offers the biotech has resorted to trimming its workforce by a quarter and cleaning out its R&D pipeline. |
Sponsored by Questex Fierce Life Sciences and Healthcare sit down with biotech, pharma, and healthcare executives at Fierce JPM Week. |
By Nick Paul Taylor Applied Therapeutics has claimed a victory in its phase 3 SORD fight, setting up plans to talk to the FDA about filing for approval, although a flip-flopping stock price points to questions over the results. |
By Max Bayer The National Institutes of Health is investing $515 million more into long Covid research efforts, three years after launching the initiative with $1.15 billion. |
By Gabrielle Masson Biofourmis has reeled in partnerships with four undisclosed Big Pharmas centered on developing digital biomarkers and safety monitoring algorithms in cancer trials. |
By Andrea Park Roche has participated in all of Freenome’s previous fundraising sessions and was also responsible for the $290 million contribution at the start of 2022 that brought Freenome’s total past the $1 billion mark. |
By Angus Liu Biogen’s business has been in decline thanks to fierce multiple sclerosis competition and a botched Alzheimer’s drug launch. To make matters worse, the U.S. Department of Justice is looking into the company’s foreign operations. |
By Joseph Keenan KGK Science, a Canadian CRO focused on health and wellness, signed a partnership with Predictmedix AI, which provides health screening and remote patient care solutions. |
By Nick Paul Taylor Eli Lilly is reminding the world of the decades of work that finally brought it to the cusp of an approval in Alzheimer’s disease. In an emotive TV spot, the drugmaker shows how people with the condition write notes to remember before ending with the line, “30 years of research hasn’t forgotten them.” |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” we explore the most anticipated drug launches of 2024. Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028. |
|
|---|
|
|
|
Wednesday, February 28, 2024 | 11am ET / 8am PT While oral minitablets can offer several advantages in pharmaceutical applications, manufacturing them can be a complex challenge. Join industry experts for a discussion on the intricate journey of drug development, with a look at how minitablets have redefined formulation strategies, efficacy, patient-centric solutions, options for lifecycle management, and more. Sign up now!
|
|
| Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
